Description
Jeffery L. Wolf, MD, University of California San Francisco, San Francisco, CA
Recorded on May 27, 2021
In this episode, Dr. Jeffrey Wolf, from the UCSF Helen Diller Family Comprehensive Cancer Center at the University of California San Francisco, explains what measurable residual disease (MRD) is, how providers can explain the role of MRD to patients, including understanding the tests used, how to counsel patients when there is MRD, where testing is done for patients treated in the community, the way MRD test results will be used in the future, and so much more. Tune in today as Dr. Wolf explores MRD with our moderator, Dr. Ken Miller!
Jeffrey L. Wolf, MD
Clinical Professor, Department of Medicine
Director, Myeloma Program
UCSF Helen Diller Family Comprehensive Cancer Center
University of California San Francisco
San Francisco, CA
This podcast episode is supported by Amgen.
Jennifer R. Rushton, MD, Clinical Pathology Associates and the Baptist Health System, San Antonio, TX and Eric Severson, MD, PhD, Labcorp Oncology, Shelton, CT
Recorded on July 2, 2024
Join us, as we dive into the crucial topic of biomarker testing with Dr. Jennifer Rushton...
Published 10/25/24
Stacie B. Dusetzina, PhD, Vanderbilt University Medical Center, Nashville, TN and Bethany Lilly, JD, The Leukemia & Lymphoma Society, Rye Brook, NY
Recorded on September 20, 2024
Tune in to this informative episode as Dr. Stacie Dusetzina from Vanderbilt University and...
Published 10/11/24